{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Dianthus Therapeutics, Inc.
Is Dianthus Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Dianthus Therapeutics, Inc. shows a mildly bullish trend, supported by bullish daily moving averages and weekly MACD, despite a bearish weekly RSI and mixed KST signals, with a notable 30.04% return over the past month and 2397.10% over three years.
Is Dianthus Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Dianthus Therapeutics, Inc. shows a mildly bullish trend with mixed technical indicators, including a bullish weekly MACD and bearish weekly RSI, while outperforming the S&P 500 significantly over the past month and year-to-date.
Is Dianthus Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Dianthus Therapeutics, Inc. shows a mildly bullish trend with mixed technical indicators, including a bullish weekly MACD and bearish weekly RSI, while outperforming the S&P 500 significantly over both 1-month and 3-year periods.
Dianthus Therapeutics Hits New 52-Week High of $40.16
Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 40.16, significantly up from its low of USD 13.37, reflecting an impressive year-over-year performance. With a market cap of USD 1,024 million, the company faces challenges, including negative return on equity and no dividend yield, amid a competitive biotechnology landscape.
Dianthus Therapeutics Hits Day High with 9.79% Surge in Stock Price
Dianthus Therapeutics, Inc. has seen a notable rise in stock performance, gaining 9.79% today and reaching an intraday high of USD 40.16. Over the past month, the stock has increased by 61.73%, despite facing challenges with negative results in recent quarters.
Is Dianthus Therapeutics, Inc. technically bullish or bearish?
As of September 5, 2025, Dianthus Therapeutics, Inc. shows a bullish technical trend with strong momentum indicators, having outperformed the S&P 500 significantly over the past month and year-to-date.
Is Dianthus Therapeutics, Inc. overvalued or undervalued?
As of March 21, 2024, Dianthus Therapeutics, Inc. is rated as risky due to its negative earnings, high valuation ratios, and poor long-term performance, despite a recent short-term gain of 85.45%.
Dianthus Therapeutics Hits New 52-Week High of $39.87
Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 39.87, reflecting an 81.09% increase over the past year. With a market capitalization of USD 1,024 million, the company has shown resilience despite losses, and its stock has significantly outperformed the S&P 500 during the same period.
Dianthus Therapeutics Hits New 52-Week High at $39.70
Dianthus Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and demonstrating strong performance compared to the S&P 500. With a market capitalization of USD 1,024 million, the company remains a notable player in the competitive pharmaceuticals and biotechnology sector despite ongoing losses.
Is Dianthus Therapeutics, Inc. overvalued or undervalued?
As of March 21, 2024, Dianthus Therapeutics, Inc. is rated as "risky" and overvalued, with key ratios indicating a Price to Book Value of 1.84, an EV to Sales ratio of 52.61, and a negative P/E ratio of -5.51, while its year-to-date stock performance has declined by 21.10% compared to the S&P 500's 2.44% gain.
Is Dianthus Therapeutics, Inc. technically bullish or bearish?
As of June 20, 2025, the technical trend has shifted to a moderately strong bearish stance, supported by bearish MACD and moving averages, mildly bearish Bollinger Bands, and underperformance relative to the S&P 500.
Who are in the management team of Dianthus Therapeutics, Inc.?
As of March 2022, the management team of Dianthus Therapeutics, Inc. includes Independent Chairman Mr. Michael Bonney, President and CEO Mr. Jason Gardner, and several Independent Directors: Mr. Jeffrey Albers, Dr. Bruce Booth, Mr. Alexis Borisy, Dr. Blake Byers, and Dr. Thomas Daniel. They are responsible for guiding the company's strategic direction and operations.
What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company developing curative treatments for autoimmune diseases, blood cancers, and genetic diseases. As of March 2025, it has a market cap of $555.40 million, with net sales of $1 million and a net loss of $30 million.
How big is Dianthus Therapeutics, Inc.?
As of Jun 18, Dianthus Therapeutics, Inc. has a market capitalization of 555.40 million, with net sales of 6.52 million and a net profit of -100.73 million over the last four quarters. The company's shareholder's funds are 352.48 million, and total assets amount to 374.24 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
